Branded Pharmacy News
Bydureon BCise features a continuous-release delivery system that provides consistent levels of the product’s active ingredient, exenatide, to help patients maintain glycemic control, the company said.
Yescarta, from Gilead’s recently acquired company Kite, was approved to treat relapsed or refractory large B-cell lymphoma following two or more lines of systemic therapy.
As specialty growth looks set to plateau, the drug class continues to see its share of per-capita spending increase, with a decline in spending on traditional medicines creating space for more specialty share.
Allergan said that the decision was not the end of the road for their intellectual property protection efforts around Restasis.
The organization has named Amgen chairman and CEO Robert Bradway to the chairman-elect position, effective immediately, and named two more industry executives to the board.
The Food and Drug Administration on Thursday approved Lyrica CR (pregabalin) controlled-release tablets.
Lupin acquired the company for $150 million, bringing into its drug portfolio Symbiomix’s recently approved single-dose treatment for bacterial vaginosis.
The Food and Drug Administration approved the product in June to treat diabetes.
The drug is a formulation featuring the company’s NovoLog insulin aspart developed with the aim of achieving properties that more closely match the natural physiological insulin mealtime response of someone without diabetes.